利用乙肝疫苗接种巩固功能性治愈：重新激活慢性乙肝病毒感染中的体液免疫轴。 - Suppr

Leveraging hepatitis B vaccination to consolidate functional cure: reigniting the humoral axis in chronic HBV infection.

作者信息

Ren Shan, Zheng Sujun, Chen Xinyue

机构信息

First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.

出版信息

Emerg Microbes Infect. 2025 Dec;14(1):2547723. doi: 10.1080/22221751.2025.2547723. Epub 2025 Aug 26.

DOI:10.1080/22221751.2025.2547723

PMID:40802993

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12381986/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3526/12381986/ade455a2a26a/TEMI_A_2547723_F0001_OC.jpg

相似文献

Leveraging hepatitis B vaccination to consolidate functional cure: reigniting the humoral axis in chronic HBV infection.

Emerg Microbes Infect. 2025 Dec;14(1):2547723. doi: 10.1080/22221751.2025.2547723. Epub 2025 Aug 26.

Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.

J Hepatol. 2024 May;80(5):714-729. doi: 10.1016/j.jhep.2023.12.032. Epub 2024 Feb 7.

The HBV seroprevalence and immune responses to hepatitis B vaccination among college students from four universities in China.

Vaccine. 2025 Aug 13;61:127408. doi: 10.1016/j.vaccine.2025.127408. Epub 2025 Jun 24.

Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study.

Virol J. 2025 May 19;22(1):146. doi: 10.1186/s12985-025-02761-3.

Enhanced hepatitis B virus-specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection.

Hepatology. 2025 Aug 1;82(2):470-486. doi: 10.1097/HEP.0000000000001179. Epub 2024 Dec 9.

Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.

J Hepatol. 2024 Dec;81(6):960-970. doi: 10.1016/j.jhep.2024.06.033. Epub 2024 Jul 9.

Vaccines for preventing hepatitis B in health-care workers.

Cochrane Database Syst Rev. 2005 Oct 19(4):CD000100. doi: 10.1002/14651858.CD000100.pub3.

Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure.

Braz J Infect Dis. 2023 Nov-Dec;27(6):103703. doi: 10.1016/j.bjid.2023.103703. Epub 2023 Nov 27.

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.

Virol J. 2024 Mar 30;21(1):77. doi: 10.1186/s12985-024-02344-8.

Evaluation of anti-HBs seropositivity rates in children with familial mediterranean fever.

Eur J Pediatr. 2025 May 29;184(6):372. doi: 10.1007/s00431-025-06221-6.

本文引用的文献

A greater frequency of circulating CCR7loPD-1hi follicular helper T cells indicates a durable clinical cure after Peg IFN-α therapy in chronic hepatitis B patients.

Hepatol Commun. 2025 Apr 14;9(5). doi: 10.1097/HC9.0000000000000690. eCollection 2025 May 1.

The core cellular network modulates immune phenotype switching in hepatitis B.

Sci Bull (Beijing). 2025 Sep 15;70(17):2717-2720. doi: 10.1016/j.scib.2025.03.038. Epub 2025 Mar 15.

The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses.

Gastroenterology. 2025 Mar 3. doi: 10.1053/j.gastro.2025.02.016.

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment.

Virol J. 2024 Oct 3;21(1):243. doi: 10.1186/s12985-024-02522-8.

A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.

Nature. 2024 Jul;631(8022):867-875. doi: 10.1038/s41586-024-07630-7. Epub 2024 Jul 10.

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.

Virol J. 2024 Mar 30;21(1):77. doi: 10.1186/s12985-024-02344-8.

Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity.

J Hepatol. 2024 Jul;81(1):42-61. doi: 10.1016/j.jhep.2024.02.017. Epub 2024 Feb 28.

Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.

J Hepatol. 2024 May;80(5):714-729. doi: 10.1016/j.jhep.2023.12.032. Epub 2024 Feb 7.

Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure.

Braz J Infect Dis. 2023 Nov-Dec;27(6):103703. doi: 10.1016/j.bjid.2023.103703. Epub 2023 Nov 27.

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance.

Hum Vaccin Immunother. 2023 Dec 31;19(1):2161254. doi: 10.1080/21645515.2022.2161254. Epub 2023 Jan 22.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Leveraging hepatitis B vaccination to consolidate functional cure: reigniting the humoral axis in chronic HBV infection.

作者信息

Ren Shan, Zheng Sujun, Chen Xinyue

机构信息

First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.

出版信息

Emerg Microbes Infect. 2025 Dec;14(1):2547723. doi: 10.1080/22221751.2025.2547723. Epub 2025 Aug 26.

DOI:10.1080/22221751.2025.2547723

PMID:40802993

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12381986/

Abstract

摘要

相似文献

Leveraging hepatitis B vaccination to consolidate functional cure: reigniting the humoral axis in chronic HBV infection.

Emerg Microbes Infect. 2025 Dec;14(1):2547723. doi: 10.1080/22221751.2025.2547723. Epub 2025 Aug 26.

Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.

J Hepatol. 2024 May;80(5):714-729. doi: 10.1016/j.jhep.2023.12.032. Epub 2024 Feb 7.

The HBV seroprevalence and immune responses to hepatitis B vaccination among college students from four universities in China.

Vaccine. 2025 Aug 13;61:127408. doi: 10.1016/j.vaccine.2025.127408. Epub 2025 Jun 24.

Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study.

Virol J. 2025 May 19;22(1):146. doi: 10.1186/s12985-025-02761-3.

Enhanced hepatitis B virus-specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection.

Hepatology. 2025 Aug 1;82(2):470-486. doi: 10.1097/HEP.0000000000001179. Epub 2024 Dec 9.

Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.

J Hepatol. 2024 Dec;81(6):960-970. doi: 10.1016/j.jhep.2024.06.033. Epub 2024 Jul 9.

Vaccines for preventing hepatitis B in health-care workers.

Cochrane Database Syst Rev. 2005 Oct 19(4):CD000100. doi: 10.1002/14651858.CD000100.pub3.

Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure.

Braz J Infect Dis. 2023 Nov-Dec;27(6):103703. doi: 10.1016/j.bjid.2023.103703. Epub 2023 Nov 27.

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.

Virol J. 2024 Mar 30;21(1):77. doi: 10.1186/s12985-024-02344-8.

Evaluation of anti-HBs seropositivity rates in children with familial mediterranean fever.

Eur J Pediatr. 2025 May 29;184(6):372. doi: 10.1007/s00431-025-06221-6.

本文引用的文献

A greater frequency of circulating CCR7loPD-1hi follicular helper T cells indicates a durable clinical cure after Peg IFN-α therapy in chronic hepatitis B patients.

Hepatol Commun. 2025 Apr 14;9(5). doi: 10.1097/HC9.0000000000000690. eCollection 2025 May 1.

The core cellular network modulates immune phenotype switching in hepatitis B.

Sci Bull (Beijing). 2025 Sep 15;70(17):2717-2720. doi: 10.1016/j.scib.2025.03.038. Epub 2025 Mar 15.

The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses.

Gastroenterology. 2025 Mar 3. doi: 10.1053/j.gastro.2025.02.016.

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment.

Virol J. 2024 Oct 3;21(1):243. doi: 10.1186/s12985-024-02522-8.

A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.

Nature. 2024 Jul;631(8022):867-875. doi: 10.1038/s41586-024-07630-7. Epub 2024 Jul 10.

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function.

Virol J. 2024 Mar 30;21(1):77. doi: 10.1186/s12985-024-02344-8.

Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity.

J Hepatol. 2024 Jul;81(1):42-61. doi: 10.1016/j.jhep.2024.02.017. Epub 2024 Feb 28.

Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels.

J Hepatol. 2024 May;80(5):714-729. doi: 10.1016/j.jhep.2023.12.032. Epub 2024 Feb 7.

Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure.

Braz J Infect Dis. 2023 Nov-Dec;27(6):103703. doi: 10.1016/j.bjid.2023.103703. Epub 2023 Nov 27.

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance.

Hum Vaccin Immunother. 2023 Dec 31;19(1):2161254. doi: 10.1080/21645515.2022.2161254. Epub 2023 Jan 22.

Leveraging hepatitis B vaccination to consolidate functional cure: reigniting the humoral axis in chronic HBV infection.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Leveraging hepatitis B vaccination to consolidate functional cure: reigniting the humoral axis in chronic HBV infection.

作者信息

机构信息

出版信息

相似文献

本文引用的文献